Company intelligence / Profile preview
KBio
- Ownership
- Private
- Development stage
- Preclinical
Overview
KBio leverages its proprietary RP3 platform to rapidly develop high-purity antibody therapies and vaccines using plants. The company claims its approach enables faster progression to clinical studies compared to industry norms, with demonstrated ability to produce novel drug candidates at lower cost. Its pipeline includes both preclinical and early-stage clinical programs targeting rare diseases, infectious disease threats, and pandemic preparedness.
- Therapeutic areas
- Rare DiseasesInfectious Diseases
- Modalities
- Antibodies (including monoclonal antibodies)VaccinesRecombinant proteins and bioactive compounds produced via plant expression systems
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on KBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBio.